Truscreen Commences Export of Second Generation Devices

Monday 2nd May 2016

Cancer technology company TruScreen Limited (NZAX: TRU) advises that supply and export of its second generation cervical cancer screening device, known as TruScreen Ultra, has commenced with initial shipments to Latin America (Mexico) and the Middle East (Jordan).

This shipment of the TruScreen Ultra device follows the recent announcement that the second generation device had been successful in gaining CE certification, thereby opening up the European Union and other select markets including the Middle East and Latin America.

TruScreen Limited CEO, Martin Dillon said: "We are very pleased to announce that supply of our new second generation Ultra device has commenced with initial shipments going to Mexico and Jordan. We had already targeted Mexico as a significant market opportunity for TruScreen and it is pleasing to note that the company has now initiated a new sales channel into the Middle East with our first shipments to Jordan. Now that we have CE certification of the new device, we are focused on expediting the manufacture and further supply of TruScreen Ultra into market as quickly as possible.

TruScreen is the only device in the world that is a CE certified, stand-alone real time primary screening tool for Cervical Cancer. TruScreen has successfully combined the use of both optical and electrical tissue differentiation to create a clinically acceptable level of performance in the primary screening of cervical cancer.

Maurice Greenough, Investment Adviser, Equity Investment Advisers Ltd comments "It is refreshing to see a New Zealand biotechnology company making progress on the world stage. The biomedical sector can be a hard nut to crack, as Pacific Edge Biotech has experienced."

Comments from our readers

No comments yet